This company listing is no longer active
Amyris (AMRS.Q) Stock Overview
Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
AMRS.Q Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Amyris, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.002 |
| 52 Week High | US$1.32 |
| 52 Week Low | US$0.000001 |
| Beta | 5.03 |
| 1 Month Change | -20.00% |
| 3 Month Change | 100.00% |
| 1 Year Change | -99.75% |
| 3 Year Change | -99.98% |
| 5 Year Change | -99.95% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
What Does Amyris, Inc.'s (NASDAQ:AMRS) Share Price Indicate?
Apr 12
Does This Valuation Of Amyris, Inc. (NASDAQ:AMRS) Imply Investors Are Overpaying?
Mar 22At US$2.95, Is Amyris, Inc. (NASDAQ:AMRS) Worth Looking At Closely?
Oct 31Amyris Cost Breakdown
Oct 07Recurring Marketing Exclusivity Deals Accelerate Amyris On Path To Profitability
Oct 01Are Investors Undervaluing Amyris, Inc. (NASDAQ:AMRS) By 43%?
Sep 02Amyris: In Dire Need For Additional Capital
Aug 22Amyris, Inc. (NASDAQ:AMRS) Just Reported, And Analysts Assigned A US$10.91 Price Target
Aug 12Amyris' Vertically-Integrated Business Model Transitioning From Investment Mode To Payoff Mode
Aug 08Amyris: Revenues Need To Catch Expenses
Jul 08Amyris: Elevated Cash Usage Causes Investors To Head For The Exits
May 11Amryis Update: Building Value One Brick At A Time
Apr 28Shareholder Returns
| AMRS.Q | US Chemicals | US Market | |
|---|---|---|---|
| 7D | 100.0% | 2.0% | 0.4% |
| 1Y | -99.7% | -1.1% | 12.5% |
Return vs Industry: AMRS.Q underperformed the US Chemicals industry which returned 9.1% over the past year.
Return vs Market: AMRS.Q underperformed the US Market which returned 25.1% over the past year.
Price Volatility
| AMRS.Q volatility | |
|---|---|
| AMRS.Q Average Weekly Movement | 8,966.3% |
| Chemicals Industry Average Movement | 6.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.7% |
Stable Share Price: AMRS.Q's share price has been volatile over the past 3 months.
Volatility Over Time: AMRS.Q's weekly volatility has increased from 4451% to 8966% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 1,598 | Han Kieftenbeld | amyris.com |
Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names.
Amyris, Inc. Fundamentals Summary
| AMRS.Q fundamental statistics | |
|---|---|
| Market cap | US$744.65k |
| Earnings (TTM) | -US$614.55m |
| Revenue (TTM) | US$268.22m |
Is AMRS.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMRS.Q income statement (TTM) | |
|---|---|
| Revenue | US$268.22m |
| Cost of Revenue | US$369.78m |
| Gross Profit | -US$101.55m |
| Other Expenses | US$512.99m |
| Earnings | -US$614.55m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.65 |
| Gross Margin | -37.86% |
| Net Profit Margin | -229.12% |
| Debt/Equity Ratio | -145.2% |
How did AMRS.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/07 12:45 |
| End of Day Share Price | 2024/05/07 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amyris, Inc. is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| J. Horwitz | Baird |
| Carter Driscoll | B. Riley Securities, Inc. |
| Susan Anderson | Canaccord Genuity |